Abstract
Dengue virus (DENV) poses a continuous threat to the public health of the global community with over 390 million infections and 25,000 deaths annually. The efficacy of the only licensed dengue vaccine, Dengvaxia, against all four DENV serotypes is less than desirable in real-world setting. In addition, there is a lack of clinically approved antiviral drugs against DENV. This drives an urgent need for the development of novel dengue therapeutics. Technological advancements in recent years have paved the way towards initiating an interest in the development of peptide drugs by the pharmaceutical industry. This chapter highlights the current status of the development of antiviral peptides targeting DENV, strategies that were utilized to design antiviral peptides, interactions that were identified between antiviral peptides and DENV host cell receptors or enzymes, advantages and disadvantages of antiviral peptides, as well as potential ways to overcome their limitations.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
